

# Lupus Nephritis- What's Up?

Agnes B. Fogo, M.D.

Vanderbilt University Medical Center,  
Nashville, TN



## 27 yo man with SLE

---

### • Previous bx 2009:

- Membranous class V and diffuse LN class IV
- One glomerulus with collapse
- Remission in response to aggressive RX




- Now marked NS, increased Screat

- Renal biopsy is essential

- What do we expect, what can we learn from biopsy in this patient?

# Lupus Nephritis- Not Just One Entity

Up to 60% of patients with SLE develop lupus nephritis



classification of lupus nephritis is essential for treatment decisions

21-23 ноября 2019 г.

**The diagnosis of SLE is NOT  
made by renal biopsy**

практическая конференция РДО  
21-23 ноября 2019 г.  
**RATHER**

**Renal biopsy defines the TYPE  
of renal lesion in a patient with  
SLE**

практическая конференция РДО  
21-23 ноября 2019 г.

# Renal Biopsy Questions to Answer in the Patient with SLE and Kidney Disease

---

-**Lupus nephritis** (IC in glomeruli)

If present, what class?

Active or chronic?

-**Vascular lesion**- TMA/vasculitis

-**Tubular deposits**

-**"Podocytopathy"**- MCD like or collapsing lesions

-**Non-lupus renal disease**

-**Lupus + non-lupus disease**

Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.

**Wide Spectrum of Lesions**

**Wide Spectrum of Implications**

**➔ Need for Classification**

XIV Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.

## Abbreviated Current ISN/RPS classification of lupus glomerulonephritis

---

**Class I Minimal mesangial LGN**

**Class II Mesangial proliferative LGN**

**Class III Focal LGN**


**Class IV Diffuse segmental (IV-S) or global (IV-G) LGN**

**Class V Membranous LGN**

**Class VI Advanced stage LGN**

Доклад А. Фого


Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.



Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого



Общероссийская научно-

практическая конференция РДО

21-23 ноября 2019 г.

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.


Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

# Доклад А. Фого



Общероссийская научно-практическая конференция РДО

21-23 ноября 2019 г.

# Доклад А. Фого

XIV Общероссийская научно-практическая конференция РДО

21-23 ноября 2019 г.

# Membranous Lupus Nephritis

---

- **Subepithelial deposits**

- **IgG, C3**


- **Varying GBM reaction  
±sclerosis**


Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого


XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.






Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.


Доклад А. Фого  
XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.



Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого  
XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.





Институт биологии  
и экологии  
Иркутского государственного  
университета  
Иркутск, 23 ноября 2019 г.  
Международная научно-  
техническая конференция ИДО  
1-2 ноября 2019



Доклад А. Фого

Общероссийская научно-  
исследовательская конференция ИДО  
2010 года

Ученые России  
вместе  
с нами  
вперед

Доклад А. Фого

## Lupus Nephritis- Class III and IV

- **Often nephritic ± nephrotic proteinuria**

(subendothelial deposits)

“Bad active” lesions- cellular crescents, necrosis,  
proliferative,

Or

“Bad chronic”- fibrous/fibrocellular crescents, sclerosis

- **Bad prognosis**

Доклад А. Фого

ХIV Общероссийская научно-  
практическая конференция РДО


21-23 ноября 2019 г.


Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого


XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.






Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого  
XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.




Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.  
Доклад А. Фого  
МГУ Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.



Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.


Доклад А. Фого  
XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.



Copyright © 1998 by the National Kidney Foundation


**Subendothelial deposits-  
In Class II and IV LN**





Key	
Orange	Endothelial cells
Purple	Podocytes
Red	Mesangial cells
Light blue	GBM
Dark gray	Matrix
Bright green	Interposed cells
Pink	Inflammatory cells
Yellow	Parietal epithelial cells
Medium gray	(not colored) Deposits

Доклад А. Фого  
Общероссийская научно-практическая конференция РДО  
21-23 ноября 2019 г.  
Доклад А. Фого  
Общероссийская научно-практическая конференция РДО  
21-23 ноября 2019 г.




**Class I**




**Class II**



**Class III/IV**



**Class V**



**Class III/IV + V**













**Class III/IV**

Pictures drawn by  
Charles Jennette


Mesangial LN (class I/II)

“Proliferative” LN (class III/IV)

Membranous LN (class V)



# Clinical Correlates Of Varying Patterns of Injury




## Presenting Features of Different LN Classes


Clinical Feature	I	II	III	IV-G	IV-S	V	VI
	n=5	n=54	n=107	n=111	n=87	n=159	n=18
Asymptomatic hematuria	40	19	22	4	6	5	0
Asymptomatic proteinuria	40	42	25	7	6	13	0
Nephrotic syndrome	20	15	17	40	38	65	11
Nephritic syndrome	0	20	34	27	26	7	0
Acute kidney injury	0	4	2	18	16	2	0
Chronic kidney disease	0	0	0	4	8	8	89
	100%	100%	100%	100%	100%	100%	100%

# Simplified Approach to Lupus Nephritis Patterns


---



**'mesangial'**



**'proliferative'**



**'membranous'**

Общероссийская научно-

практическая конференция РДО

21-23 ноября 2019 г.


Доклад А. Фого

У IV Общероссийская научно-

практическая конференция РДО


21-23 ноября 2019 г.

# Simplified Approach to Lupus Nephritis Patterns




Present in < 50% of glomeruli

Active or Chronic?



Present in  $\geq$  50% of glomeruli

Active or Chronic? Segmental / Global?



# The Final Result of Experts' Work Over Long Time...

Доклад А. Фого

Table 3. International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus nephritis

<b>Class I</b>	<b>Minimal mesangial lupus nephritis</b> Normal glomeruli by light microscopy, but mesangial immune deposits by immunofluorescence
<b>Class II</b>	<b>Mesangial proliferative lupus nephritis</b> Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with mesangial immune deposits May be a few isolated subepithelial or subendothelial deposits visible by immunofluorescence or electron microscopy, but not by light microscopy
<b>Class III</b>	<b>Focal lupus nephritis<sup>a</sup></b> Active or inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving <50% of all glomeruli, typically with focal subendothelial immune deposits, with or without mesangial alterations
Class III (A)	Active lesions: focal proliferative lupus nephritis
Class III (A/C)	Active and chronic lesions: focal proliferative and sclerosing lupus nephritis
Class III (C)	Chronic inactive lesions with glomerular scars: focal sclerosing lupus nephritis
<b>Class IV</b>	<b>Diffuse lupus nephritis<sup>b</sup></b> Active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving $\geq 50\%$ of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. This class is divided into diffuse segmental (IV-S) lupus nephritis when $\geq 50\%$ of the involved glomeruli have segmental lesions, and diffuse global (IV-G) lupus nephritis when $\geq 50\%$ of the involved glomeruli have global lesions. Segmental is defined as a glomerular lesion that involves less than half of the glomerular tuft. This class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation
Class IV-S (A)	Active lesions: diffuse segmental proliferative lupus nephritis
Class IV-G (A)	Active lesions: diffuse global proliferative lupus nephritis
Class IV-S (A/C)	Active and chronic lesions: diffuse segmental proliferative and sclerosing lupus nephritis
Class IV-S (C)	Chronic inactive lesions with scars: diffuse segmental sclerosing lupus nephritis
Class IV-G (C)	Chronic inactive lesions with scars: diffuse global sclerosing lupus nephritis
<b>Class V</b>	<b>Membranous lupus nephritis</b> Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations Class V lupus nephritis may occur in combination with class III or IV in which case both will be diagnosed Class V lupus nephritis show advanced sclerosis
<b>Class VI</b>	<b>Advanced sclerosis lupus nephritis</b> $\geq 90\%$ of glomeruli globally sclerosed without residual activity

# The Natural History of the Renal Manifestations of Systemic Lupus Erythematosus

---


- Serial biopsy study in 87 SLE patients
- Poor prognosis of “active lupus nephritis”
- Response to steroids
- Rare transformation

Pollak, Pirani and Schwartz, J Lab Clin Med 1964

Доклад А. Фого

# Renal Failure Death in SLE

Общероссийская научно-практическая конференция РДО




Pollak et al, 1964

# Challenges Remain with the ISN/RPS LN Classification

- Lack of precise differentiation of types of cells in hypercellular lesions
- How many cells are too many?
- How helpful is A+C?
- Can we be more granular in describing lesions, and thus classifying?
- Interobserver variability
- Outcome-
- Level 1- Current recommendations
- Level 2- Gather unbiased data to determine significance of varying lesions

# Interobserver Variability



21-23 ноября 2019 г.

# RPS Survey on LN

Does this glomerulus contain a lesion which would put the biopsy in class III or IV?  Yes  No

If so, please also indicate

Active and/or chronic  Active  Chronic  Active/chronic

Segmental or global  Segmental  Global

Endocapillary proliferation  Present  Absent

Influx of inflammatory cells  Present  Absent

Swelling of endothelial cells  Present  Absent

Extracapillary proliferation  Present  Absent

If present  Cellular  Fibrocellular  Fibrous

Wire loops  Present  Absent

Fibrinoid necrosis  Present  Absent

Karyorrhexis  Present  Absent

Other lesions?  Yes  No If yes, please describe

Comments

21-23 ноября 2019 г.

21-23 ноября 2019 г.




# Interobserver (dis)agreement

Parameter	Statistical method	Outcome*
<b>Class III/IV</b>	ICC	0,39
<b>Active and/or chronic</b>	kappa	0,35
<b>Segmental or global</b>	kappa	0,39
<b>Endocapillary proliferation</b>	ICC	0,46
<b>Influx of inflammatory cells</b>	ICC	0,32
<b>Swelling of endothelial cells</b>	ICC	0,46
<b>Extracapillary proliferation</b>	ICC	0,57
<b>Type of crescent</b>	kappa	0,45
<b>Wire loops</b>	ICC	0,35
<b>Karyorrhexis</b>	ICC	0,29

\*>0,8 excellent; 0,6 – 0,8 good; 0,4 – 0,6 moderate; <0,4 poor

No statistically significant effect of level of experience on outcome

# Segmental or Global?



## Why do we disagree?

---

- We observe different things
- We use different definitions
- We do not know what we are doing....

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

# Why do we disagree?

Общероссийская научно-

практическая конференция РДО

21-23 ноября 2019 г.




Доклад А. Фого

XIV Общероссийская научно-

практическая конференция РДО

21-23 ноября 2019 г.


## Segmental or Global?



*Global:* A lesion involving more than half of the glomerular tuft

*Segmental:* A lesion involving less than half of the glomerular tuft (i.e., at least half of the glomerular tuft is spared)

# Clinical Significance of Segmental vs Global?



# Definitions. Matter

Общероссийская научно-


практическая конференция РДО

21-23 ноября 2019 г.


Доклад А. Фого

XIV Общероссийская научно-

практическая конференция РДО



*Ceci n'est pas une pipe.*



21-23 ноября 2019 г. *And this is not a crescent*

# Leiden Lupus Nephritis Meeting May 2016

## Aim:

To improve problematic definitions that form the basis of the LN classification and thereby increase interobserver agreement between nephropathologists worldwide who apply these definitions to classify lupus nephritis



Ingeborg Bajema, Suzanne Wilhelmus, Charles E. Alpers, Jan A. Bruijn, Robert B. Colvin, Terry Cook, Vivette D'Agati, Franco Ferrario, Mark Haas, J. Charles Jennette, Kensuke Joh, Cynthia C. Nast, Laure-Hélène Noël, Emilie Rijnink, Ian S.D. Roberts, Surya V. Seshan, Sanjeev Sethi, Agnes B. Fogo

# Leiden lupus nephritis meeting, May 2016

## **Aim:**

To improve the lupus nephritis classification using an evidence-based approach.

## **First step:**

Refining the existing definitions-

because they form the essential elements on which the classification is based.



# Two-level Approach to Improving LN Classification

---

## Level 1:

Adjust definitions for inconsistencies, vagueness, omissions.  
Minor changes to thresholds if evidence to do so already exists;  
clarifying details;  
providing useful examples that illustrate difficult issues.

## Level 2:

Evidence-based multi-center study, involving scoring of separate parameters, relation to outcome.  
Results used to guide possible modifications of the existing classification system.

# Conundrums of the mesangium in LN


---

How much hypercellularity in  
how many glomeruli?

How many cells, and how to  
combine with matrix  
expansion (cut-off)?

If only mesangial cells:  
*hyperplasia.*

If not only mesangial cells:  
*endocapillary  
hypercellularity?*



# Considerations of the mesangium in LN

---

## Level 1:


Increase threshold of mesangial hypercellularity from 3 to 4 cells/mesangial area (congruent with IgAN)

## Level 2 tasks:


-Determine cut-off to distinguish Class I vs II.

(BUT- hypercellularity in only one area in one glomerulus seems a rather low threshold.)

-Role of inflammatory cells in mesangium.



# CD68 staining in LN



# Conundrums of endocapillary lesions


---

**Endocapillary 'proliferation'**

**Types and numbers of cells involved: unclear**

**Amount of lumen reduction: unclear**

**Role of endothelial cells: unclear**



# Considerations of endocapillary lesions

---

Level 1:

Replace the term

*endocapillary proliferation*


by

*endocapillary hypercellularity*

Level 2 tasks:

Determine cut-off levels for:

- number of inflammatory cells
- extent of capillary luminal narrowing
- role of endothelial cell swelling



# Conundrums of extracapillary lesions


---

**Composition**

**Fibrous / Cellular**

**Involving  $\geq 25\%$  of  
Bowman's capsule**

**What to do with a glomerulus  
with 2 types of crescents?**



# Considerations of extracapillary lesions

---

**Nomenclature: a variable mixture of cells**

**Composition may vary from predominantly:**

- epithelial cells


**OR**

- monocytes/macrophages

**Fibrous / Cellular**

**Level 1:**

**Threshold to diagnose a crescent changed:  
from 25% of circumference involved to 10%**



# Conundrums of segmental/global lesions

---

**Clinical significance: questioned**

**Interobserver variation: large**

**Uncertain how to combine endocapillary lesions and extracapillary lesions into the segmental / global distinction**

**Part of the original discussion to indicate 'vasculitic-like' lesions lost**

**Consideration: remove segmental/global connotations**



Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО


21-23 ноября 2019 г.

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.

# Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis



# Non-immune Complex Lesions

---

- Podocytopathies
- Vascular
- TBM deposits

- Biopsy essential for specific dx-



Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО

21-23 ноября 2019 г.

# Vascular lesions in SLE

---

- **No impact on prognosis:**
  - Uncomplicated vascular deposits
- **Poor prognosis:**
  - Thrombotic microangiopathy
  - Lupus vasculopathy  
(noninflammatory necrotizing lesions with variable immune deposits)
  - Lupus vasculitis  
(necrotizing and inflammatory vasculitis with transmural infiltration of the vessel wall)

# TMA and APL and SLE

---

- TMA occurs in any class of LN,  
+/- APL

- APL Ab in 25-50% of SLE pts-  
not all with TMA

- Renal: TMA  
thromboses in large arteries  
cortical necrosis

# **Conundrums of activity/chronicity**

---

**A, C and A/C are insufficient discriminators**

**Consideration:**

**Move back to the NIH Activity/Chronicity Indices**

# Original NIH Activity/Chronicity Assessments

Table 13-4

## ACTIVITY AND CHRONICITY INDICES<sup>a</sup>

### Index of Activity (0-24)

Endocapillary hypercellularity	(0-3+)
Leukocyte infiltration	(0-3+)
Subendothelial hyaline deposits	(0-3+)
Fibrinoid necrosis/karyorrhexis	(0-3+) x 2
Cellular crescents	(0-3+) x 2
Interstitial inflammation	(0-3+)

### Index of Chronicity (0-12)

Glomerular sclerosis	(0-3+)
Fibrous crescents	(0-3+)
Tubular atrophy	(0-3+)
Interstitial fibrosis	(0-3+)

# Varying Views on A and C

Activity index (graded on a scale of 0 to 3+ for each);

total of 24

1. Endocapillary proliferation,
2. Glomerular leukocyte infiltration,
3. Wire loop deposits,
4. Fibrinoid necrosis and karyorrhexis (X2),
5. Cellular crescents (X2)
6. Interstitial inflammation

- Endocapillary hypercellularity with or without leucocyte infiltration ; luminal reduction
- Karyorrhexis
- Fibrinoid necrosis
- Rupture of GBM
- Cellular or Fibrocellular Crescents
- Subendothelial deposits on LM
- Intraluminal Immune aggregates

Activity \*  
Glomeruli

Hypercellularity

Karyorrhexis or fibrinoid necrosis

Cellular crescents \*\*

Wire loops \*\*

Leukocyte infiltration

Tubule/Interstitium

Mononuclear cell infiltration

**Activity index**

**Cellular proliferation**

**Leukocyte infiltration**

**Fibrinoid necrosis**

**Cellular crescents**

**Hyaline thrombi**

**Mononuclear infiltration**

**Activity index risk group†**

Доклад А. Фого  
Общероссийская научно-  
практическая конференция РДО

---

**A vs C, and All in Between**

**Will Await Level 2 EVIDENCE!**

Доклад А. Фого  
XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

## 27 yo man with SLE

---

### • Previous bx 2009:


- Membranous class V and diffuse LN class IV
- One glomerulus with collapse
- Remission in response to aggressive RX

- Now marked NS, increased Screat

- Renal biopsy is essential

# Collapsing GP and LN

---



# Final Diagnosis

---

- Membranous lupus nephritis, Class V
- Focal lupus nephritis (A+C)
- Collapsing GP
- More collapse, less activity of endocapillary proliferative lesions
- This severe injury is NOT captured by ISN/RPS classification

# Areas for Ongoing Consideration- Level 2 work to be done

---

- **Classification of non-glomerular lesions**
- **Further dissection of varied pathogeneses and importance of varied glomerular lesions-**
- **Add “Risk predictor score” from evidence-based study, define those responsive to specific Rx or not**
- **Possible role of AI?**

практическая конференция РДО

21-23 ноября 2019 г.

Доклад А. Фого

Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.

Доклад А. Фого

XIV Общероссийская научно-  
практическая конференция РДО  
21-23 ноября 2019 г.



**With Acknowledgments and Thanks to the Leiden Working Group  
And to Ingeborg Bajema for spearheading this project**

